Dr. Sekulic on Molecular Testing in Advanced Melanoma

Video

In Partnership With:

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

There are various molecular tests that can be viewed as an adjunct to diagnosis and prognosis of melanoma. It is routine to conduct molecular testing for BRAF mutation to help oncologists determine if patients will respond to BRAF inhibitors. This type of molecular testing should always be implemented, Sekulic explains.

In a broader sense, molecular testing aims to find other targets that may not have defined therapies associated with them, Sekulic says. This challenge has led researchers to form the Melanoma Dream Team for the Stand Up to Cancer trial. This will determine if patients can be treated with specific therapies based on molecular test findings and, if so, what the best practices would be used to accomplish this. Within this trial, researchers are using whole-exome sequencing and long insert whole genome sequencing.

Related Videos
Eduardo Sotomayor, MD
James Knight, MD
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Matthew Galsky, MD, professor of medicine, Hematology and Medical Oncology, director, Genitourinary Medical Oncology, codirector, Center of Excellence for Bladder Cancer, associate director, Translational Research, The Tisch Cancer Institute of Mount Sinai
Daneng Li, MD
Andre Goy, MD
Efrat Dotan, MD
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Marijo Bilusic, MD, PhD, GU site disease group lead, GU SDD medical oncology lead, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School